- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02972905
Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects
A Single Center, Double-blind, Randomized, Placebo-controlled, Parallel, Single and Repeat, Dose-ascending Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Japanese Subjects
GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3-Kinase (PI3K) delta inhibitor being developed as an anti-inflammatory and anti-infective agent for the treatment of inflammatory airway diseases, such as chronic obstructive pulmonary disease (COPD). The purpose of the study is to assess the safety, tolerability and pharmacokinetics (PK) of single and repeat doses of GSK2269557 administered via the ELLIPTA dry powder inhaler (DPI) to healthy Japanese subjects. This is the first time for Japanese subjects that GSK2269557 will be administered via the ELLIPTA DPI with the addition of magnesium stearate.
In each group of this study, subjects will receive a single dose of either GSK2269557 or placebo in Session 1 and receive daily dose of GSK2269557 or placebo for 10 days in Session 2. Session 1 of the next dose strength may be run in parallel with the Session 2 of the previous dose. The doses planned for the study are 200 micrograms (mcg), 500 mcg and 700 mcg. There will be at least 10 days washout between the two dosing sessions. Follow up period will start 10 days (+-1 day) after the last dose of Session 2. A total number of 36 subjects will be enrolled for the study with 27 subjects receiving a dose strength of GSK2269557 and 9 subjects will receive each dose strength of GSK2269557. ELLIPTA is a trademark of the GSK group of companies.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Fukuoka, Japan, 813-0017
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Participant must be 20 to 64 years of age inclusive, at the time of signing the informed consent.
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECG. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the Medical Monitor if required agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Normal spirometry (forced expiratory volume in 1 second >=80% of predicted) at Screening.
- Body weight >=50 kilograms (kg) and body mass index (BMI) within the range 18.5 to 24.9 kg/square meter (m^2) (inclusive).
- Japanese Male: A male participant must agree to use contraception of this protocol during the treatment period and until follow up visit.
- Capable of giving signed informed consent as described in restrictions listed in the informed consent form (ICF).
Exclusion Criteria
- History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study treatment; or interfering with the interpretation of data
- Abnormal blood pressure as determined by the investigator
- ALT >1.5x upper limit of normal (ULN)
- Bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
- QTcF >450 milliseconds (msec).
- Past or intended use of over-the-counter or prescription medication including herbal medications within 14 days prior to dosing.
- History of donation of blood or blood products >=400 milliliters (mL) within 3 months or >=200 mL within 1 month prior to screening
- Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day
- Current enrollment or past participation within the last 30 days before signing of consent in this clinical study involving an investigational study treatment or any other type of medical research
- The subject is positive Serological test for syphilis (rapid plasma reagin and Treponema pallidum), Human immunodeficiency virus (HIV) Antigen/Antibody, Hepatitis B surface antigen (HbsAg), Hepatitis C virus (HCV) antibody, or Human T-cell lymphotropic virus type 1 (HTLV-1) antibody at screening.
- Positive pre-study drug screen
- Regular use of known drugs of abuse
- Regular alcohol consumption within 6 months prior to the study defined as: for an average weekly intake of >14 units for males. One unit is equivalent to 350 ml of beer, 150 ml of wine or 45 ml of 80 proof distilled spirits
- Smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening
- Sensitivity to any of the study treatments, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Session 1: Placebo
Subjects will receive a single dose inhalation of GSK2269557 matching placebo via the ELLIPTA DPI.
The washout period between the two dosing sessions will be at least 10 days.
|
Placebo ELLIPTA DPI contains lactose
|
Experimental: Session 1: GSK2269557 200 mcg
Subjects will receive a single dose inhalation of GSK2269557 200 mcg via the ELLIPTA DPI.
The washout period between the two dosing sessions will be at least 10 days.
|
GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate.
This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
|
Experimental: Session 1: GSK2269557 500 mcg
Subjects will receive a single dose inhalation of GSK2269557 500 mcg via the ELLIPTA DPI.
The washout period between the two dosing sessions will be at least 10 days.
|
GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate.
This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
|
Experimental: Session 1: GSK2269557 700 mcg
Subjects will receive a single dose inhalation of GSK2269557 700 mcg via the ELLIPTA DPI.
The washout period between the two dosing sessions will be at least 10 days.
|
GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate.
This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
|
Placebo Comparator: Session 2: Placebo
Subjects will receive repeated doses of GSK2269557 matching Placebo once daily via the ELLIPTA DPI for 10 days.
The washout period between the two dosing sessions will be at least 10 days.
|
Placebo ELLIPTA DPI contains lactose
|
Experimental: Session 2: GSK2269557 200 mcg
Subjects will receive repeated doses of GSK2269577 200mcg once daily via the ELLIPTA DPI for 10 days.
The washout period between the two dosing sessions will be at least 10 days.
|
GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate.
This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
|
Experimental: Session 2: GSK2269557 500 mcg
Subjects will receive repeated doses of GSK2269577 500mcg once daily via the ELLIPTA DPI for 10 days.
The washout period between the two dosing sessions will be at least 10 days.
|
GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate.
This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
|
Experimental: Session 2: GSK2269557 700 mcg
Subjects will receive repeated doses of GSK2269577 700mcg once daily via the ELLIPTA DPI for 10 days.
The washout period between the two dosing sessions will be at least 10 days.
|
GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate.
This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with any adverse event(s) (AE) and serious adverse event(s) (SAE)
Time Frame: Approximately up to 37 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment will be categorized as SAE.
|
Approximately up to 37 days
|
Session 1: Number of subjects having abnormal clinical laboratory parameters as a measure of safety
Time Frame: Approximately up to 4 days
|
Blood samples will be collected to analyse blood urea nitrogen, creatinine, glucose (fasting), uric acid, high density lipoprotein-cholesterol, amylase, potassium, sodium, calcium, triglycerides, lactate dehydrogenase (LDH), chloride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total cholesterol, gamma-glutamyl transpeptidase (GGT), phosphorus, total bilirubin, direct bilirubin, total protein, albumin, low density lipoprotein-cholesterol, creatine phosphokinase (CPK)
|
Approximately up to 4 days
|
Session 2: Number of subjects having abnormal clinical laboratory parameters as a measure of safety
Time Frame: Approximately up to 22 days
|
Blood samples will be collected to analyse blood urea nitrogen, creatinine, glucose (fasting), uric acid, high density lipoprotein-cholesterol, amylase, potassium, sodium, calcium, triglycerides, LDH, chloride, AST, ALT, ALP, total cholesterol, GGT, phosphorus, total bilirubin, direct bilirubin, total protein, albumin, low density lipoprotein-cholesterol, CPK
|
Approximately up to 22 days
|
Session 1:Number of subjects having abnormal hematology laboratory parameters as a measure of safety
Time Frame: Approximately up to 4 days
|
Blood samples will be collected to analyse platelet count, Red Blood Cells (RBC) count, hemoglobin, hematocrit, RBC Indices, mean corpuscular volume ( MCV), mean corpuscular hemoglobin (MCH), percent reticulocytes, White Blood Cells (WBC), neutrophils, lymphocytes, monocytes, eosionophils, and basophils
|
Approximately up to 4 days
|
Session 2: Number of subjects having abnormal hematology laboratory parameters as a measure of safety
Time Frame: Approximately up to 22 days
|
Blood samples will be collected to analyse platelet count, RBC count, hemoglobin, hematocrit, RBC Indices, MCV, MCH, percent reticulocytes, WBC, neutrophils, lymphocytes, monocytes, eosionophils, and basophils
|
Approximately up to 22 days
|
Session 1: Number of subjects having abnormal urinalysis as a measure of safety
Time Frame: Approximately up to 4 days
|
Urine samples will be collected to analyse specific gravity, pH, glucose, protein, blood, ketones, bilirubin, and urobilinogen for dipstick, and microscopic examination
|
Approximately up to 4 days
|
Session 2: Number of subjects having abnormal urinalysis as a measure of safety
Time Frame: Approximately up to 22 days
|
Urine samples will be collected to analyse specific gravity, pH, glucose, protein, blood, ketones, bilirubin, and urobilinogen for dipstick, and microscopic examination
|
Approximately up to 22 days
|
Session 1: Body temperature assessment as a safety measure
Time Frame: Approximately up to 4 days
|
Temperature will be recorded in a supine position after 5 minutes rest
|
Approximately up to 4 days
|
Session 2: Body temperature assessment as a safety measure
Time Frame: Approximately up to 22 days
|
Temperature will be recorded in a supine position after 5 minutes rest
|
Approximately up to 22 days
|
Session 1: Blood pressure assessment as a safety measure
Time Frame: Approximately up to 4 days
|
Systolic and diastolic blood pressure will be measured in a supine positon after 5 minutes rest
|
Approximately up to 4 days
|
Session 2: Blood pressure assessment as a safety measure
Time Frame: Approximately up to 22 days
|
Systolic and diastolic blood pressure will be measured in a supine position after 5 minutes rest
|
Approximately up to 22 days
|
Session 1: Measurement of pulse rate as a safety measure
Time Frame: Approximately up to 4 days
|
Pulse rate will be measured in a supine position after 5 minutes rest
|
Approximately up to 4 days
|
Session 2: Measurement of pulse rate as a safety measure
Time Frame: Approximately up to 22 days
|
Pulse rate will be measured in a supine position after 5 minutes rest
|
Approximately up to 22 days
|
Session 1: Electrocardiogram (ECG) assessment as a measure of safety.
Time Frame: Approximately up to 4 days
|
Single 12-lead ECG will be obtained in a supine position after 5 minutes rest using an ECG machine that measures PR, QRS, QT, and Corrected QT interval by Fridericia's formula (QTcF) intervals.
Single ECGs will be obtained at each time point.
|
Approximately up to 4 days
|
Session 2: ECG assessment as a measure of safety.
Time Frame: Approximately up to 22 days
|
Single 12-lead ECG will be obtained in a supine position after 5 minutes rest using an ECG machine that measures PR, QRS, QT, and QTcF intervals.
Single ECGs will be obtained at each time point.
|
Approximately up to 22 days
|
Session 1: Spirometry assessment as a safety measure
Time Frame: Approximately up to 4 days
|
Spirometry assessments will be performed whilst the subject is in a standing position.
Assessments will be repeated until 3 technically acceptable measurements have been made.
|
Approximately up to 4 days
|
Session 2: Spirometry assessment as a safety measure
Time Frame: Approximately up to 22 days
|
Spirometry assessments will be performed whilst the subject is in a standing position.
Assessments will be repeated until 3 technically acceptable measurements have been made.
|
Approximately up to 22 days
|
Session 1: Area under the plasma concentration curve (AUC) from time zero to the time of last quantifiable concentration [AUC(0-t)]
Time Frame: Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72hours (h) post-dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC [0-t]
|
Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72hours (h) post-dose
|
Session 1: AUC from time zero to 24 hours post dose [AUC(0-24)] of GSK2269557 following a single dose administration
Time Frame: Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC[0-24]
|
Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose
|
Session 1: AUC from time zero to infinity [AUC(0-infinity)] of GSK2269557 following a single dose administration
Time Frame: Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC (0-infinity).
|
Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose
|
Session 2: AUC from time zero to the time of last quantifiable concentration [AUC(0-t)] of GSK2269557 following repeat dose administration
Time Frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC [0-t]
|
Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Session 2: AUC from time zero to 24 hours post dose [AUC(0-24)] of GSK2269557 following repeat dose administration
Time Frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC[0-24]
|
Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Session 2: AUC from time zero to infinity [AUC(0-infinity)] of GSK2269557 following repeat dose administration
Time Frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC (0-infinity)
|
Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Session 1: Trough observed plasma drug concentration (Ctrough) of GSK2269557 following a single dose administration
Time Frame: Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating Ctrough
|
Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose
|
Session 1: Maximum observed plasma concentration (Cmax) of GSK2269557 following a single dose administration
Time Frame: Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating Cmax
|
Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose
|
Session 1: Maximum/trough observed plasma drug concentration (Cmax/Ctrough) of GSK2269557 following a single dose administration
Time Frame: Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating Cmax/Ctrough
|
Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose
|
Session 2: Trough observed plasma drug concentration (Ctrough) of GSK2269557 following repeat dose administration
Time Frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating Ctrough
|
Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Session 2: Maximum observed plasma concentration (Cmax) of GSK2269557 following repeat dose administration
Time Frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating Cmax
|
Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Session 2: Maximum/trough observed plasma drug concentration (Cmax/Ctrough) of GSK2269557 following repeat dose administration
Time Frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating Cmax/Ctrough
|
Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Session 1: Time to maximum observed plasma drug concentration (Tmax) of GSK2269557 following a single dose administration
Time Frame: Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating tmax
|
Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose
|
Session 1: Terminal half-life (t1/2) of GSK2269557 following a single dose administration
Time Frame: Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating t1/2
|
Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose
|
Session 2: Time to maximum observed plasma drug concentration (Tmax) of GSK2269557 following repeat dose administration
Time Frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating tmax
|
Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Session 2: Terminal half-life (t1/2) of GSK2269557 following repeat dose administration
Time Frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Blood samples will be collected at pre-dose and at specific post dose time points for calculating tmax and t1/2
|
Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose
|
Ratio of accumulation factor (Ro) of GSK2269557 following single and repeat inhalations
Time Frame: Day 1 of session 2 and day 10 of session 2
|
Ro is defined as AUC(0-24) of Session 2 at day10 divided by AUC(0-24) of Session1
|
Day 1 of session 2 and day 10 of session 2
|
Ratio of accumulation factor (Rs) of GSK2269557 following single and repeat inhalations
Time Frame: Day 1 of session 2 and day 10 of session 2
|
Rs is defined as AUC(0-24) of Session 2 at day10 divided by AUC(0-infinity) of Session 1
|
Day 1 of session 2 and day 10 of session 2
|
Ratio of accumulation factor (R[Cmax]) of GSK2269557 following single and repeat inhalations
Time Frame: Day 1 of session 2 and day 10 of session 2
|
R[Cmax] is defined as Cmax of Session 2 at day10 divided by Cmax of Session 1
|
Day 1 of session 2 and day 10 of session 2
|
Ratio of accumulation factor (R[Ctrough]) of GSK2269557 following single and repeat inhalations
Time Frame: Day 1 of session 2 and day 10 of session 2
|
R[Ctrough] is defined as Ctrough of Session 2 at day10 divided by C24 of Session 1
|
Day 1 of session 2 and day 10 of session 2
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 205759
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Placebo ELLIPTA DPI
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States
-
GlaxoSmithKlineCompletedAsthmaCanada, United States
-
GlaxoSmithKlineCompletedAsthmaUnited States, Argentina, Japan, Poland, Canada, Russian Federation, Spain, Germany, Hungary, South Africa, Italy, Mexico, Romania, Bulgaria, China, Lithuania
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
Nocion TherapeuticsCompleted
-
Celon Pharma SANational Center for Research and Development, PolandCompletedMajor Depressive DisorderPoland
-
Chiesi Farmaceutici S.p.A.CompletedCOPDUnited Kingdom, Ireland